We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Seville, Spain

ICHNO 2026

Session

Thursday
March 19
14:30 - 16:00
New data from trials and multinational studies
Jean Bourhis, Switzerland;
Wojciech Golusiński, Poland
Proffered Papers
14:30 - 16:00
Safety and efficacy of SYS6043, a novel B7-H3 targeting antibody-drug conjugates, in patients with advanced nasopharyngeal carcinoma
Yuxiang Ma, China
-574
14:30 - 16:00
A Single-Arm Phase II Study of Envafolimab Combined with Chemoradiotherapy and Recombinant Human Endostatin in High-risk Locally Advanced Nasopharyngeal Carcinoma
Sui Jiang-dong, China
-592
14:30 - 16:00
Discussant
Paolo Bossi, Italy
14:30 - 16:00
Induction toripalimab plus chemotherapy followed by selective chemoradiation de-escalation in HPV-positive oropharyngeal cancer: a single-arm, phase 2 trial (IChoice-02)
Xueguan Lu, China
-586
14:30 - 16:00
Treatment Strategies and Survival in Oropharyngeal Cancer Across the Nordic Countries: Epidemiological insights from 23 years of multinational data
Christian von Buchwald, Denmark
-598
14:30 - 16:00
Discussant
Silke Tribius, Germany
14:30 - 16:00
Neoadjuvant and adjuvant pembrolizumab plus standard of care in LA HNSCC: Outcomes by postoperative risk in the PD-L1 CPS ≥1 population of KEYNOTE-689
Irene Brana, Spain
-595
14:30 - 16:00
Induction and Adjuvant Camrelizumab Combined with Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (CRIA): A Multicenter, Phase II trial
Ying Wang, China
-593
14:30 - 16:00
Discussant
Shao Hui Huang, Canada